CYP2D6 increases toxicity of the designer drug 4-methylthioamphetamine (4-MTA)

Toxicology

Volumn 229, Issue 3, 2007, Pages 236-244

  Carmo, Helena ^a   Brulport, Marc ^b   Hermes, Matthias ^b   Oesch, Franz ^c   de Boer, Douwe ^d   Remião, Fernando ^a   Carvalho, Félix ^a   Schön, Michael R ^b   Krebsfaenger, Niels ^e   Doehmer, Johannes ^f   Bastos, Maria de Lourdes ^a   Hengstler, Jan G ^b  

^a Faculdade de Farmácia da Universidade do Porto   (Portugal)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Schwarz Pharma AG   (Germany)

^f GenPharmTox BioTech AG   (Germany)

Author keywords

4 Methylthioamphetamine; CYP2D6; Designer drugs; Hepatotoxicity; Metabolism; Polymorphism

Indexed keywords

4 METHYLTHIOAMPHETAMINE; AMPHETAMINE DERIVATIVE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DESIGNER DRUG; ISOENZYME;

ALLELE; ANIMAL CELL; ARTICLE; CHINESE HAMSTER; COLONY FORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; GENE; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; LUNG FIBROBLAST; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

AMPHETAMINES; ANIMALS; CELL LINE; CELL SURVIVAL; CRICETINAE; CRICETULUS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DESIGNER DRUGS; GENOTYPE;

CRICETULUS GRISEUS;

EID: 33845580694     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2006.10.024     Document Type: Article

References (63)

1. Asghar S.J., Tanay V.A., Baker G.B., Greenshaw A., and Silverstone P.H. Relationship of plasma amphetamine levels to physiological, subjective, cognitive and biochemical measures in healthy volunteers. Hum. Psychopharmacol. 18 (2003) 291-299
2. Bach M.V., Coutts R.T., and Baker G.B. Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica 29 (1999) 719-732
3. Baggott M., Heifets B., Jones R.T., Mendelson J., Sferios E., and Zehnder J. Chemical analysis of ecstasy pills. JAMA 284 (2000) 2190
4. Bertilsson L., Dahl M.L., Dalen P., and Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 53 (2002) 111-122
5. Capela J.P., Meisel A., Abreu A.R., Branco P.S., Ferreira L.M., Lobo A.M., Remiao F., Bastos M.L., and Carvalho F. Neurotoxicity of ecstasy metabolites in rat cortical neurons, and influence of hyperthermia. J. Pharmacol. Exp. Ther. 316 (2006) 53-61
6. Carmo H., Brulport M., Hermes M., Oesch F., Silva R., Ferreira L.M., Branco P.S., de Boer D., Remião F., Carvalho F., Schön M.R., Krebsfaenger N., Doehmer J., Bastos M.L., and Hengstler J.G. Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine ("Ecstasy") cytotoxicity. Pharmacogenet Genomics 16 (2006) 789-799
7. Carmo H., de Boer D., Remião F., Carvalho F., Reys L.A., and Bastos M.L. Identification of 4-methylthioamphetamine and some of its metabolites in mouse urine by GC-MS after acute administration. J. Anal. Toxicol. 26 (2002) 228-232
8. Carmo H., Hengstler J.G., de Boer D., Ringel M., Carvalho F., Fernandes E., Remiao F., Reys L.A., Oesch F., and Bastos M.L. Comparative metabolism of the designer drug 4-methylthioamphetamine by hepatocytes from man, monkey, dog, rabbit, rat and mouse. Naunyn Schmiedebergs Arch. Pharmacol. 369 (2004) 198-205
9. Carmo H., Hengstler J.G., de Boer D., Ringel M., Remiao F., Carvalho F., Fernandes E., Reys L.A., Oesch F., and Bastos M.L. Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human. Toxicology 206 (2005) 75-89
10. Carmo H., Remiao F., Carvalho F., Fernandes E., de Boer D., Reys L.A., and Bastos M.L. 4-Methylthioamphetamine-induced hyperthermia in mice: influence of serotonergic and catecholaminergic pathways. Toxicol. Appl. Pharmacol. 190 (2003) 262-271
11. Carvalho M., Hawksworth G., Milhazes N., Borges F., Monks T.J., Fernandes E., Carvalho F., and Bastos M.L. Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells. Arch. Toxicol. 76 (2002) 581-588
12. Carvalho M., Milhazes N., Remiao F., Borges F., Fernandes E., Amado F., Monks T.J., Carvalho F., and Bastos M.L. Hepatotoxicity of 3,4-methylenedioxyamphetamine and alpha-methyldopamine in isolated rat hepatocytes: formation of glutathione conjugates. Arch. Toxicol. 78 (2004) 16-24
13. Carvalho M., Remiao F., Milhazes N., Borges F., Fernandes E., Carvalho F., and Bastos M.L. The toxicity of N-methyl-alpha-methyldopamine to freshly isolated rat hepatocytes is prevented by ascorbic acid and N-acetylcysteine. Toxicology 200 (2004) 193-203
14. Carvalho M., Remiao F., Milhazes N., Borges F., Fernandes E., Monteiro M., Goncalves M.J., Seabra V., Amado F., Carvalho F., and Bastos M.L. Metabolism is required for the expression of ecstasy-induced cardiotoxicity in vitro. Chem. Res. Toxicol. 17 (2004) 623-632
15. Colado M.I., Williams J.L., and Green A.R. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the dark agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br. J. Pharmacol. 115 (1995) 1281-1289
16. de Boer D., Egberts T., and Maes R.A.A. Para-methylthioamphetamine, a new amphetamine designer drug of abuse. Pharm. World Sci. 21 (1999) 47-48
17. Decaestecker T., de Letter E.A., Clauwaert K., Bouche M.P., Lambert W., Bocxlaer J.V., Piette M., Eeckhout E.V.D., Peteghem C.V., and de Leenheer A. Fatal 4-MTA intoxication: development of a liquid chromatographic-tandem mass spectrometric assay for multiple matrices. J. Anal. Toxicol. 25 (2001) 705-710
18. de la Torre R., Farre M., Mathuna B.O., Roset P.N., Pizarro N., Segura M., Torrens M., Ortuno J., Pujadas M., and Cami J. MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. Eur. J. Clin. Pharmacol. 61 (2005) 551-554
19. de Letter E.A., Bouche M.P., Bocxlaer J.F.V., Lambert W.E., and Piette M.H. Interpretation of a 3,4-methylenedioxymethamphetamine (MDMA) blood level: discussion by means of a distribution study in two fatalities. Forensic Sci. Int. 141 (2004) 85-90
20. de Letter E.A., Coopman V.A.E., Cordonnier J.A.C.M., and Piette M.H.A. One fatal and seven non-fatal cases of 4-methylthioamphetamine (4-MTA) intoxication: clinico-pathological findings. Int. J. Legal Med. 114 (2001) 352-356
21. de Letter E.A., Piette M.H., Lambert W.E., and Cordonnier J.A. Amphetamines as potential inducers of fatalities: a review in the district of Ghent from 1976-2004. Med. Sci. Law 46 (2006) 37-65
22. Dukat M., Young R., and Glennon R.A. Effect of PMA optical isomers and 4-MTA in PMMA-trained rats. Pharmacol. Biochem. Behav. 72 (2002) 299-305
23. Easton N., Fry J., O'Shea E., Watkins A., Kingston S., and Marsden C.A. Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy). Brain Res. 987 (2003) 144-154
24. Elliott S.P. Fatal poisoning with a new phenethylamine: 4-methylthioamphetamine (4-MTA). J. Anal. Toxicol. 24 (2000) 85-89
25. Escobedo I., O'Shea E., Orio L., Sanchez V., Segura M., de la Torre R., Farre M., Green A.R., and Colado M.I. A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice. Br. J. Pharmacol. 144 (2005) 231-241
26. European Communities. Council decision of 13 September 1999 defining 4-MTA as a new synthetic drug which is to be made subject to control measures and criminal penalties. Official Journal of the European Communities (1999) p. 1
27. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Report on the Risk Assessment of 4-MTA in the Framework of the Joint Action on New Synthetic Drugs (1999), Office for official publications of the European Communities, Luxembourg 3-114
28. Ewald A.H., Peters F.T., Weise M., and Maurer H.H. Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine (4-MTA) in human urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 824 (2005) 123-131
29. Farré M., de la Torre R., Mathuna B.O., Roset P.N., Peiró A.M., Torrens M., Ortuno J., Pujadas M., and Camí J. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacol. 173 (2004) 364-375
30. Forsling M.L., Fallon J.K., Shah D., Tilbrook G.S., Cowan D.A., Kicman A.T., and Hutt A.J. The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br. J. Pharmacol. 135 (2002) 649-656
31. Garcia-Repetto R., Moreno E., Soriano T., Jurado C., Gimenez M.P., and Menendez M. Tissue concentrations of MDMA and its metabolite MDA in three fatal cases of overdose. Forensic Sci. Int. 135 (2003) 110-114
32. Gilhooly T.C., and Daly A.K. CYP2D6 deficiency, a factor in ecstasy related deaths?. Br. J. Clin. Pharmacol. 54 (2002) 69-70
33. Gollamudi R., Ali S.F., Lipe G., Newport G., Webb P., Lopez M., Leakey J., Kolta M., and Slikker W.J. Influence of inducers and inhibitors on the metabolism in vitro and neurochemical effects in vivo of MDMA. Neurotoxicology 10 (1989) 455-466
34. Greene S.L., Dargan P.I., O'Connor N., Jones A.L., and Kerins M. Multiple toxicity from 3,4-methylenedioxymethamphetamine ("ecstasy"). Am. J. Emerg. Med. 21 (2003) 121-124
35. Hartung T.K., Schofield E., Short A.I., Parr M.J., and Henry J.A. Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion. Q.J.M. 95 (2002) 431-437
36. Henry J.A., and Hill I.R. Fatal interaction between ritonavir and MDMA. Lancet 352 (1998) 1751-1752
37. Henry J.A., Jeffreys K.J., and Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340 (1992) 384-387
38. Huang X., Marona-Lewicka D., and Nichols D.E. p-Methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. Eur. J. Pharmacol. 229 (1992) 31-38
39. Hurtado-Guzman C., Martinez-Alvarado P., Dagnino-Subiabre A., Paris I., Caviedes P., Caviedes R., Cassels B.K., and Segura-Aguilar J. Neurotoxicity of some MAO inhibitors in adult rat hypothalamic cell culture. Neurotox. Res. 4 (2002) 161-163
40. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5 (2005) 6-13
41. Jones A.L., and Simpson K.J. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment. Pharmacol. Ther. 13 (1999) 129-133
42. Jones D.C., Duvauchelle C., Ikegami A., Olsen C.M., Lau S.S., de la Torre R., and Monks T.J. Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J. Pharmacol. Exp. Ther. 313 (2005) 422-431
43. Kavanagh P.V., Corrigan D., Maguire R.T., Meegan M.J., Keating J.J., Clancy J., and Burdett J. Excretion profile of 4-methylthioamphetamine in dogs. Pharm. Pharmacol. Commun. 5 (1999) 653-655
44. Khorana N., Pullagurla M.R., Dukat M., Young R., and Glennon R.A. Stimulus effects of three sulfur-containing psychoactive agents. Pharmacol. Biochem. Behav. 78 (2004) 821-826
45. Krebsfaenger N., Murdter T.E., Zanger U.M., Eichelbaum M.F., and Doehmer J. V79 Chinese hamster cells genetically engineered for polymorphic cytochrome P450 2D6 and their predictive value for humans. ALTEX 20 (2003) 143-154
46. Li Q., Murakami I., Stall S., Levy A.D., Brownfield M.S., Nichols D.E., and Van de Kar L.D. Neuroendocrine pharmacology of three serotonin releasers: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (MBDB), 5-methoxy-6-methyl-2-aminoindan (MMAI) and p-methylthioamphetamine (MTA). J. Pharmacol. Exp. Ther. 279 (1996) 1261-1267
47. Malpass A., White J.M., Irvine R.J., Somogyi A.A., and Bochner F. Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and dark agouti rats. Pharmacol. Biochem. Behav. 64 (1999) 29-34
48. Mas M., Farre M., de la Torre R., Roset P.N., Ortuno J., Segura J., and Cami J. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J. Pharmacol. Exp. Ther. 290 (1999) 136-145
49. O'Donohoe A., O'Flynn K., Shields K., Hawi Z., and Gill M. MDMA toxicity: no evidence for a major influence of metabolic genotype at CYP2D6. Addict. Biol. 3 (1998) 309-314
50. Poortman A.J., and Lock E. Analytical profile of 4-methylthioamphetamine (4-MTA), a new street drug. Forensic Sci. Int. 100 (1999) 221-233
51. Ramamoorthy Y., Tyndale R.F., and Sellers E.M. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 11 (2001) 477-487
52. Ramamoorthy Y., Yu A., Suh N., Haining R.L., Tyndale R.F., and Sellers E.M. Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem. Pharmacol. 63 (2002) 2111-2119
53. Schwab M., Seyringer E., Brauer R.B., Hellinger A., and Griese E.U. Fatal MDMA intoxication. Lancet 353 (1999) 593-594
54. Scorza M.C., Carrau C., Silveira R., Zapata-Torres G., Cassels B.K., and Reyes-Parada M. Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives. Biochem. Pharmacol. 54 (1997) 1361-1369
55. Segura M., Farre M., Pichini S., Peiro A.M., Roset P.N., Ramirez A., Ortuno J., Pacifici R., Zuccaro P., Segura J., and de la Torre R. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. Clin. Pharmacokinet. 44 (2005) 649-660
56. Simantov R., and Tauber M. The abused drug MDMA (ecstasy) induces programmed death of human serotonergic cells. FASEB J. 11 (1997) 141-146
57. Smilkstein M.J., Smolinske S.C., and Rumack B.H. A case of MAO inhibitor/MDMA interaction: agony after ecstasy. J. Toxicol. Clin. Toxicol. 25 (1987) 149-159
58. Sporer K.A. The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf. 13 (1995) 94-104
59. Stumm G., Schlegel J., Schafer T., Wurz C., Mennel H.D., Krieg J.C., and Vedder H. Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons. FASEB J. 13 (1999) 1065-1072
60. Tucker G.T., Lennard M.S., Ellis S.W., Woods H.F., Cho A.K., Lin L.Y., Hiratsuka A., Schmitz D.A., and Chu T.Y. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem. Pharmacol. 47 (1994) 1151-1156
61. Vuori E., Henry J.A., Ojanpera I., Nieminen R., Savolainen T., Wahlsten P., and Jantti M. Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction 98 (2003) 365-368
62. World Health Organization (WHO). WHO Expert Committee on Drug Dependence. Thirty-second report. World Health Organ. Tech. Rep. Ser. 903 (2001) 1-26
63. Zanger U.M., Raimundo S., and Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 369 (2004) 23-37